Nathan Brown Quoted by POLITICO on Drug Quality and Security Act
Contact:
POLITICO blog Prescription Pulse, for its article “Unsolicited Advice on Drug Labeling Rule, Compounding,” quoted Akin Gump health care and life sciences partner Nathan Brown on the genesis of the 2013 Drug Quality and Security Act.
Brown, an FDA policy advisor to the Senate HELP Committee at the time the law was drafted, said that the Act was created to draw a “bright line of demarcation between pharmacy practice and outsourcing,” noting that states would be responsible for overseeing pharmacists compounding drugs with an individual patient prescription, whereas the FDA would supervise outsourcers compounding drugs without specific prescriptions.
People Mentioned in This News
© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.